22 / 27
4
2
0
–2
–4
CR: 0/33 (0%)
PR: 5/33 (15%)
SD: 8/33 (24%)
PD: 20/33 (61%)
CR: 2/23 (9%)
PR: 5/23 (22%)
SD: 9/23 (39%)
PD: 7/23 (30%)
CR: 1/55 (2%)
PR: 14/55 (25%)
SD: 17/55 (31%)
PD: 23/55 (42%)
CR: 1/66 (2%)
PR: 11/66 (17%)
SD: 15/66 (23%)
PD: 39/66 (59%)
CR
PR
SD
PD
4
2
0
–2
–4
Molecular subtype
Response
PD-L1 expression
Luminal
Basal
Interferon-γ
Luminal 1
Luminal 2
Basal 1
Basal 2
High
Medium
Low
Basal 2
Basal 1
Luminal 2
Luminal 1
–2
0
CR/PR/SD
PD
–1
Signature scor
Response
Type
CXCL10
CXCL9
STAT1
IDO1
CD74
CD4
CXCR6
CD3D
IL2RB
CD2
CCR5
CXCL13
CD27
PRF1
GZMB
LAG3
GZMA
CD8A
CCL5
PTPRC
IFNG
CXCL11
TBX21
PDCD1
EGFR
CD44
KRT16
KRT14
KRT5
KRT6A
CDH3
CDKN2A
PPARG
GATA3
KRT7
ERBB3
ERBB2
FOXA1
KRT19
FGFR3
XBP1
CD24
KRT8
KRT18
Molecular subtype
PD-L1 expression
Response
C
:
Heatmap of 25-gene
feron-γ signature (A),
ion between 25-gene
feron-γ signature and
nse to nivolumab (B),
d heatmap of 25-gene
rferon-γ signature by
molecular subtype of
othelial carcinoma (C)
R=complete response.
D=progressive disease.
ial response. SD=stable
disease.
Sharma, P et al. Lancet Oncol 2017
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275)
N=270
benefit to nivolumab in metastatic
urothelial carcinoma